Safety, Pharmacokinetics and Antiviral Effect of BI 201335 NA in HCV-1 Infected Patients Treated for 28 Days for Treatment naive and Experienced Patients Treated in Combination With Peg Interferon Alfa-2a and Ribavirin

Trial Profile

Safety, Pharmacokinetics and Antiviral Effect of BI 201335 NA in HCV-1 Infected Patients Treated for 28 Days for Treatment naive and Experienced Patients Treated in Combination With Peg Interferon Alfa-2a and Ribavirin

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2015

At a glance

  • Drugs Faldaprevir (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 26 Apr 2012 Official title amended as reported by ClinicalTrials.gov.
    • 26 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top